Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05881304 · ClinicalTrials.gov registry record · NA

Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC

A NA study of Electronic Cigarette Use, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT05881304: Recruiting NA study of Electronic Cigarette Use, sponsored by Massachusetts General Hospital.

NCT05881304 is a NA study of Electronic Cigarette Use that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 40 participants, below the 210-participant average among 15 other Electronic Cigarette Use trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05881304, a NA study of Electronic Cigarette Use, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to conduct a pilot randomized waitlist-controlled trial to assess the feasibility, acceptability, and preliminary effects of substituting the NIDA standardized research e-cigarette (SREC) for combusted cigarettes in MOUD-TUD who are not ready to quit smoking. A waitlist controlled RCT using a mixed-methods sequential explanatory design will investigate the impact of SREC provision on: 1) tobacco use behavior (e.g., cigarettes per day \[primary outcome\], SREC use), 2) biomarkers (e.g., carbon monoxide, anabasine), 3) cigarette dependence and withdrawal, and 4) short-term health effects and tolerability (e.g., respiratory symptoms, substance use). In the proposed RCT, N=40 adults stable on MOUD with buprenorphine who report daily smoking recruited from MGH primary care practices will be randomly assigned to receive the SREC for 8 weeks, either immediately (iSREC), or after an 8-week delay (waitlist control \[WLC\]). They will be followed an additional 4 weeks after SREC provision ends (to 12 weeks in iSREC and 20 weeks in WLC).

Primary Outcome

Change in cigarettes smoked per day (CPD) between randomized groups. Change in mean number of CPD in the past 7 days from Baseline 2 to Week 8 comparing between randomized groups (iSREC group vs. WLC).

Conditions Studied

Interventions

  • DEVICE Standardized research e-cigarette (SREC)

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-06-03
Est. Completion 2026-06-01
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT05881304 shows while recruiting

NCT05881304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 210-participant average among 15 other Electronic Cigarette Use trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Electronic Cigarette Use appearing as the primary indexed condition, and to 1 intervention - of which Standardized research e-cigarette (SREC) is the first listed.

NCT05881304 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05881304 about?

NCT05881304 is a clinical study titled "Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC". The goal of this study is to conduct a pilot randomized waitlist-controlled trial to assess the feasibility, acceptability, and preliminary effects of substituting the NIDA standardized research e-cigarette (SREC) for combusted cigarettes in MOUD-TUD who are not ready to quit smoking. A waitlist con...

What is the current status of trial NCT05881304?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2024-06-03. Estimated completion is 2026-06-01.

What conditions does trial NCT05881304 study?

This clinical trial studies the following conditions: Electronic Cigarette Use.

What interventions are being tested in trial NCT05881304?

The interventions under investigation include: Standardized research e-cigarette (SREC) (DEVICE).

Who is sponsoring clinical trial NCT05881304?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05881304 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Electronic Cigarette Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05881304's enrollment target sits among peer trials

40 11th of 15 higher than 5 of 15 other Electronic Cigarette Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Electronic Cigarette Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05881304, the US trial registry maintained by the National Library of Medicine. NCT05881304 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.